tetano
Editor, Senior Moderator
Med Sci Monit
. 2021 Nov 25;27:e934267.
doi: 10.12659/MSM.934267.
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
Giovanni Franchin[SUP] 1 [/SUP], Nikhitha Mantri[SUP] 2 [/SUP], Maleeha Zahid[SUP] 2 [/SUP], Haozhe Sun[SUP] 2 [/SUP], Sudharsan R Gongati[SUP] 2 [/SUP], Diana M Ronderos[SUP] 2 [/SUP], Snigdha Gadireddy[SUP] 2 [/SUP], Sridhar Chilimuri[SUP] 2 [/SUP]
Affiliations
Abstract
BACKGROUND The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic diseases. Patients with rheumatologic diseases are usually on long-term corticosteroids and immunosuppressive therapy, which increases their risk for progressing to more severe forms of COVID-19. We report a case series of 4 patients with rheumatologic diseases who were treated with MAT for COVID-19. MATERIAL AND METHODS A retrospective observational study was conducted in our institution on patients with underlying rheumatological disorders who received MAT as per the EUA protocol of the FDA. RESULTS Two of the 4 patients were on immunosuppresive therapy at the time of receiving MAT. They recovered from COVID-19 without any adverse outcomes. No flare of underlying rheumatologic disease was noted. CONCLUSIONS MAT was observed to be a safe and effective therapy in 4 patients with rheumatological illnesses and COVID-19 treated at our hospital.
. 2021 Nov 25;27:e934267.
doi: 10.12659/MSM.934267.
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders
Giovanni Franchin[SUP] 1 [/SUP], Nikhitha Mantri[SUP] 2 [/SUP], Maleeha Zahid[SUP] 2 [/SUP], Haozhe Sun[SUP] 2 [/SUP], Sudharsan R Gongati[SUP] 2 [/SUP], Diana M Ronderos[SUP] 2 [/SUP], Snigdha Gadireddy[SUP] 2 [/SUP], Sridhar Chilimuri[SUP] 2 [/SUP]
Affiliations
- PMID: 34819488
- DOI: 10.12659/MSM.934267
Abstract
BACKGROUND The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic diseases. Patients with rheumatologic diseases are usually on long-term corticosteroids and immunosuppressive therapy, which increases their risk for progressing to more severe forms of COVID-19. We report a case series of 4 patients with rheumatologic diseases who were treated with MAT for COVID-19. MATERIAL AND METHODS A retrospective observational study was conducted in our institution on patients with underlying rheumatological disorders who received MAT as per the EUA protocol of the FDA. RESULTS Two of the 4 patients were on immunosuppresive therapy at the time of receiving MAT. They recovered from COVID-19 without any adverse outcomes. No flare of underlying rheumatologic disease was noted. CONCLUSIONS MAT was observed to be a safe and effective therapy in 4 patients with rheumatological illnesses and COVID-19 treated at our hospital.